Transthyretin (ATTR) Amyloidosis
View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.
Publications
Transthyretin Amyloidosis (ATTR)
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
American Journal of Transplantation
Transthyretin Amyloidosis (ATTR)
Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program
Circulation: Genomic and Precision Medicine
Transthyretin Amyloidosis (ATTR)
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
The Lancet Neurology
Transthyretin Amyloidosis (ATTR)
Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank
Amyloid
Transthyretin Amyloidosis (ATTR)
Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates
Nucleic Acids Research
Transthyretin Amyloidosis (ATTR)
DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis
Amyloid
